Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Update
by Scott Moore · The Cerbat GemMolecular Partners AG Sponsored ADR (NASDAQ:MOLN – Get Free Report) was the target of a significant decline in short interest during the month of April. As of April 15th, there was short interest totaling 12,887 shares, a decline of 20.4% from the March 31st total of 16,194 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 3,644 shares, the short-interest ratio is presently 3.5 days.
Molecular Partners Trading Up 0.2%
MOLN stock traded up $0.01 during trading on Friday, hitting $4.24. The company had a trading volume of 1,982 shares, compared to its average volume of 2,579. The business has a 50 day moving average of $4.47 and a 200 day moving average of $4.30. Molecular Partners has a fifty-two week low of $3.41 and a fifty-two week high of $5.36. The firm has a market capitalization of $171.21 million, a price-to-earnings ratio of -2.13 and a beta of 1.09.
Molecular Partners (NASDAQ:MOLN – Get Free Report) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.03). As a group, equities analysts predict that Molecular Partners will post -1.4 EPS for the current year.
Analyst Ratings Changes
A number of equities analysts have commented on MOLN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Molecular Partners in a report on Friday, April 10th. TD Cowen reissued a “buy” rating on shares of Molecular Partners in a report on Monday, March 16th. Finally, HC Wainwright reissued a “buy” rating and set a $13.00 price target on shares of Molecular Partners in a report on Wednesday, April 22nd. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.38.
View Our Latest Stock Report on Molecular Partners
Institutional Investors Weigh In On Molecular Partners
A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC purchased a new position in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN – Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 12,311 shares of the company’s stock, valued at approximately $54,000. Hedge funds and other institutional investors own 26.55% of the company’s stock.
About Molecular Partners
Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.
The company’s development pipeline spans infectious diseases, ophthalmology and oncology.